ArticleBiomedical reports2026
Clozapine (and norclozapine) concentrations are correlated with functioning, disability and side-effects when patients are treated with clozapine without the availability of therapeutic drug monitoring: A study of treatment-resistant schizophrenia inpatients.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clozapine levels in inpatients with schizophrenia are not a predictor of rehospitalization: a naturalistic retrospective study.Pharmacological reports : PR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In numerous countries, including Serbia, therapeutic drug monitoring (TDM) for clozapine is unavailable, leaving dose adjustments based solely on clinical judgment, could increase risk of therapeutic failure or adverse outcomes. The present study aimed to assess associations between clozapine and norclozapine serum concentrations, measured via Dried Blood Spot (DBS), and symptom severity, functioning, disability, and side effects in Serbian inpatients with treatment-resistant schizophrenia (TRS). In a cross-sectional design, patients with TRS with ongoing clozapine treatment and who did not meet exclusion criteria, were to be included. For clinical assessments of symptom severity, functionality, disability and side effects, were used: Simplified Interview for Negative and Positive Symptoms (SNAPSI), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), WHO Disability Assessment Schedule (WHODAS) and the Clozapine Adverse Effects Scale (GASS-C). Spearman's analysis showed no significant correlation between GASS-C scores and clozapine dose or plasma levels. WHODAS scores showed significant positive correlations with clozapine dose (ρ=0.409, P=0.006), clozapine (ρ=0.333, P=0.038) and norclozapine (ρ=0.481, P=0.002) levels. GAF scores negatively correlated with clozapine (ρ=-0.354, P=0.027) and norclozapine (ρ=-0.370, P=0.020). GASS-C scores were significantly associated with female sex (P=0.003), body mass index (BMI; ρ=-0.678, P<0.0005) and WHODAS scores (ρ=0.372, P=0.014). Regression analysis identified clozapine dose, clozapine level, BMI, SNAPSI and CGI scores as significantly associated with GASS-C (P=0.045). Norclozapine, BMI and CGI scores significantly associated with WHODAS (P=0.018). In the present study, it was found that clozapine and norclozapine concentrations are significantly associated with functioning, disability and side effects in patients with TRS treated without TDM. DBS-based monitoring may offer a valuable alternative for optimizing treatment. Further longitudinal studies are needed to clarify the clinical utility of (nor) clozapine level-guided care in such settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.